Combination biologic therapy for ulcerative colitis

Article Gastroenterology & Hepatology

Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial

Brian G. Feagan et al.

Summary: This study compared the efficacy of combination therapy with guselkumab and golimumab to monotherapy for ulcerative colitis, and found that combination therapy achieved a higher clinical response rate at 12 weeks. However, these findings need to be confirmed in larger trials.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2023)

添加到收藏夹

Editorial Material Biotechnology & Applied Microbiology

Bispecific antibodies for the treatment in inflammatory bowel disease: an avenue worth exploring?

Benedicte Caron et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Breaking Through the Therapeutic Ceiling: What Will It Take?

Tim Raine et al.

Summary: There is a high level of uncertainty in the treatment response for patients starting a new treatment for inflammatory bowel disease. To overcome the current limitations, improvements are needed in areas such as diagnosis, treatment stratification, response monitoring, and clinical trial design.

GASTROENTEROLOGY (2022)

添加到收藏夹

Review Gastroenterology & Hepatology

Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Waseem Ahmed et al.

Summary: Dual biologic or small molecule therapy may be a possible option in highly selected, refractory IBD patients at specialized centers. However, higher quality combination of therapies and significant improvement in the quality of data are required prior to more widespread use.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease

Kevin J. Roberts et al.

Summary: Anti-TNF alpha and anti-IL-23 antibodies are effective therapies for Crohn's disease or ulcerative colitis, and a novel bispecific domain antibody V56B2 shows potential for treating IBD with improved safety and efficacy. V56B2 combines a llama-derived IL-23p19-specific domain antibody with a previously-described TNF alpha-specific domain antibody, demonstrating stability in the intestinal milieu and the ability to inhibit tissue phosphoprotein levels in colonic biopsies from IBD patients.

SCIENTIFIC REPORTS (2021)

添加到收藏夹

Article Dermatology

Comparative Efficacy and Relative Ranking of Biologics and Oral Therapies for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis

April W. Armstrong et al.

Summary: This study evaluated the efficacy of biologic and oral treatments for moderate-to-severe psoriasis, finding that ixekizumab, risankizumab, and brodalumab had the highest short-term efficacy, while risankizumab demonstrated the highest long-term efficacy.

DERMATOLOGY AND THERAPY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study

Andres J. Yarur et al.

GUT (2016)

添加到收藏夹

Article Medicine, General & Internal

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.

Jean Frederic Colombel et al.

NEW ENGLAND JOURNAL OF MEDICINE (2010)

添加到收藏夹

Combination biologic therapy for ulcerative colitis

相关参考文献

导出引文

分享论文